9TH DRESDEN SYMPOSIUM ON AUTOANTIBODIES

DRESDEN, SEPTEMBER 2–5, 2009

FINAL PROGRAMME

www.gfid-ev.de
Karsten Conrad, Werner Schößler, Falk Hiepe, Marvin J. Fritzler

Autoantibodies in Systemic Autoimmune Diseases – A Diagnostic Reference
second Edition
ISBN 978-3-89967-420-0

Autoantibodies are a very heterogeneous group of antibodies with respect to their specificity, induction, effects, and clinical significance. Testing for autoantibodies can be helpful or necessary for the diagnosis, differential diagnosis, prognostication, or monitoring of autoimmune diseases. In case of limited (forme fruste) disease or a single disease manifestation, the detection of serum autoantibodies can play an important role in raising the suspicion of evolving disease and forecasting prognosis. This book and reference guide is intended to assist the physician in understanding and interpreting the variety of autoantibodies that are being used as diagnostic and prognostic tools for patients with systemic rheumatic diseases. Autoantibodies observed in systemic autoimmune diseases are described in alphabetical order in Part 1 of this reference guide. In Part 2, systemic autoimmune disorders as well as symptoms that indicate the possible presence of an autoimmune disease are listed. Systemic manifestations of organ-specific autoimmune diseases will not be covered in this volume. Guide marks were inserted to ensure fast and easy cross-reference between symptoms, a given autoimmune disease and associated autoantibodies. Although the landscape of autoantibody testing continues to change, this information will be a useful and valuable reference for many years to come.
Dear Colleagues,

On behalf of the Organizing Committee it is a great pleasure to welcome you to the 9th Dresden Symposium on Autoantibodies.

The Symposium is organised by the Institute of Immunology of the Medical Faculty of the Technical University Dresden and the “Gesellschaft zur Förderung der Immundiagnostik e.V." (Society for the Advancement of Immune Diagnostics). The goal is to bring together clinicians and scientists specialising in "autoimmunology" to exchange academic information and to present and discuss the results of basic and applied research on autoantigens, autoantibodies and autoimmunity.

In the spectrum of immunological diseases affecting various organs by inflammation and/or fibrosis, autoimmune reactions play an important role. Based on different studies both in humans as well as in animal models it becomes obvious that there is a broad range of pathologies that involve not only “primary“ autoimmune reactions but also other pathogenic mechanisms such as postinfectious and autoinflammatory processes. The heterogeneity within the immunological diseases may reflect the variable expression of autoinflammatory, autoimmune, and up to now unknown factors in disease development and manifestation. The current Dresden Symposium on Autoantibodies entitled “From Pathogenesis to Therapy of Autoimmune diseases“ will focus on different aspects of the pathogenesis of autoimmune and autoimmune-like diseases, the detection of novel and the relevance of esoteric autoantibodies, and biological therapies. The clarification of the etiopathological mechanisms is required to optimize prophylaxis, diagnostics and therapy of autoimmune diseases. Especially, the application of novel and designer biological therapies needs a better understanding of the processes that are involved in the genesis of immunological diseases. Some findings of the role of epigenetic mechanisms and innate immunity in the
pathogenesis of autoimmune diseases may offer novel prophylactic and therapeutic strategies. Regardless of the underlying pathology, disease-associated autoantibodies are important biomarkers for the vast majority of non-organ and organ specific autoimmune diseases. However, to improve our understanding of these diseases and serological diagnostics it is necessary to search for novel autoantibodies, to further evaluate the real clinical relevance of known autoantibodies and to further develop and standardize the detection methods. The current symposium highlights novel insights into the immune dysregulation, pathogenesis, serological diagnostics and biological therapies of autoimmune diseases with the main focus on rheumatoid arthritis, systemic lupus erythematosus, and autoimmune neurological diseases.

We would like to express our thanks to the members of the International Advisory Board and to the active contributors who will present their latest achievements as well as to the many sponsors who enabled this symposium. We expect that our 9th Dresden Symposium on Autoantibodies will stimulate a broad debate how the new achievements from the bench work could help to improve diagnostics and therapy of autoimmune diseases. We hope that you will enjoy the scientific programme and your stay in Dresden.

With best wishes,
Karsten Conrad
On behalf of the Organizing Committee
Registration

Welcome and Introduction

THE SPECTRUM AND PATHOGENESIS OF NONINFECTIOUS INFLAMMATORY AND SCLEROSING DISEASES
Co-Chairs: K. Conrad (Dresden, Germany)  
P. von Landenberg (Olten, Switzerland)

The autoimmune – autoinflammatory continuum  
Michael McDermott (Leeds, UK)

Autoimmune pancreatitis and IgG4-related sclerosing diseases  
Terumi Kamisawa (Tokyo, Japan)

Autoallergy – chronic inflammation by IgE autoreactivity  
Rudolf Valenta (Vienna, Austria)

COFFEE BREAK – POSTER AND EXHIBITION VIEWING

BIOLOGICAL THERAPY OF AUTOIMMUNE DISEASES I
Co-Chairs: G. Steiner (Vienna, Austria)  
C. Chizzolini (Geneva, Switzerland)

Advances in targeted therapies  
Joseph Smolen (Vienna, Austria)

The role of B cells in immunoregulation  
Elias Toubi (Haifa, Israel)
Targeting of memory plasma cells as therapeutic option in autoimmune diseases
Falk Hiepe (Berlin, Germany)

* Peptide-based immunotherapy of dilated cardiomyopathy in a Lewis rat model
Vladimir Kocoski (Würzburg, Germany)

Welcome Reception
PATHOGENETIC ASPECTS OF AUTOIMMUNE DISEASES

Co-Chairs: F. Hiepe (Berlin, Germany)
E. Toubi (Haifa, Israel)

The mosaic of autoimmunity – Autoantibodies, prediction and therapy
Yehuda Shoenfeld (Tel-Hashomer, Israel)

The mosaic of the etiopathogenesis of SLE – Role of chromatin binding autoantibodies
Martin Herrmann (Erlangen, Germany)

A mutation in TREX1 that impairs susceptibility to granzyme A mediated cell death causes familial chilblain lupus
Min Ae Lee-Kirsch (Dresden, Germany)

* Antiphospholipid antibodies affect the process of angiogenesis: novel mechanism of placental damage
Silvia d’Ippolito (Rome, Italy)

COFFEE BREAK – POSTER AND EXHIBITION VIEWING

Poster viewing
P1-P7 Novel autoantibodies
P8-P11 Methodical aspects
P12-P13 Therapy
THE ROLE OF EPIGENETICS AND INNATE IMMUNITY IN THE PATHOGENESIS OF AUTOIMMUNE DISEASES
Co-Chairs: E.K.L. Chan (Gainesville, USA)
M. Herrmann (Erlangen, Germany)

10.45–11.15
Epigenetic mechanisms in the induction and aggravation of autoimmunity
Olga Sánchez-Pernaute (Madrid, Spain)

11.15–11.35
Toll-like receptors and autoimmunity
Philipp von Landenberg (Olten, Switzerland)

11.35–11.55
Proteinase 3 and its receptors: linking innate to autoimmunity in ANCA-associated vasculitides
Elena Csernok (Lübeck, Germany)

11.55–12.15
Antifibroblast antibodies and Toll-like receptors in the pathogenesis of systemic sclerosis
Carlo Chizzolini (Geneva, Switzerland)

12.15–12.30
* Epigenetic regulation of IL-10 expression: The role of activation dependent changes in DNA methylation patterns in CD4+ T cell subsets
Christian M. Hedrich (Dresden, Germany)

12.30–13.30
LUNCH BREAK – POSTER AND EXHIBITION VIEWING

Poster viewing
P19-P26 Vasculitides/ANCA
NOVEL AND ESOTERIC AUTOANTIBODIES

Co-Chairs: C. Casiano (Loma Linda, USA)
R.L. Humbel (Luxembourg)

The clinical paradox of esoteric and novel autoantibodies
Marvin Fritzler (Calgary, Canada)

Anti-RNA helicase A as a new serologic marker of early SLE
Minoru Satoh (Gainesville, USA)

Identification of Rho-GTPase-activating protein
p26 as a novel autoantigen
Martin Blüthner (Karlsruhe, Germany)

Identification of the β- and γ-subunits of F1-ATPase
as target antigens in anti-M2/PDC-E2 negative primary
biliary cirrhosis (PBC)
Beate Preuß (Tübingen, Germany)

* Sperm-associated antigen 16 isoform 2:
A novel candidate autoantigen in multiple sclerosis
Klaartje Somers (Diepenbeek, Belgium)

Anti-p155/140 (anti-TIF1) autoantibodies in patients
with cancer associated myositis detected in a single centre
Jiri Vencovsky (Prague, Czech Republic)

COFFEE BREAK - POSTER AND EXHIBITION VIEWING
**THURSDAY**  
**SEPTEMBER 03**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 16.00–17.30| **MOLECULAR MIMICRY AND AUTOIMMUNE DISEASES**  
**Co-Chairs:**  
Y. Shoenfeld (Tel-Hashomer, Israel)  
A. Ebringer (London, UK)  
Molecular mimicry in ankylosing spondylitis and rheumatoid arthritis  
*Alan Ebringer (London, UK)*  
Polymyalgia rheumatica, blindness and anti-Proteus antibodies  
*Roland Pechlaner (Innsbruck, Austria)*  
*Vaccination and autoimmunity*  
*Nancy Agmon-Levin (Tel-Hashomer, Israel)* |
| 16.30–18.30| **PRESENTATIONS OF YOUNG SCIENTISTS**  
**Co-Chairs:**  
K. Conrad (Dresden, Germany)  
U. Sack (Leipzig, Germany)  
*Gender differences in oxidative stress and apoptosis of vascular cells induced by autoantibodies specific to RLIP76*  
*Tania Colasanti (Rome, Italy)*  
*Immortalized B cell lines from multiple sclerosis patients produce antibodies that bind an oligodendrocyte precursor cell line*  
*Judith Fraussen (Diepenbeek, Belgium)*  
*Analysis of autoantibody profiles in cerebrospinal fluid and serum of a relapsing-remitting MS patient with active disease using Serological Antigen Selection*  
*Cindy Govarts (Diepenbeek, Belgium)* |
* Anti-CENP-A and anti-CENP-B antibodies show high concordance and similar clinical associations in patients with systemic sclerosis despite completely different underlying protein sequences
Katharina Hanke (Potsdam, Germany)

* Anti-argonaute2 (Ago2/Su) and -Ro antibodies are the common autoantibody specificities in primary anti-phospholipid syndrome (PAPS)
Angela Ceribelli (Brescia, Italy)

* β1-adrenoreceptor autoantibodies in a Lewis rat model of dilated cardiomyopathy
Vladimir Kocoski (Würzburg, Germany)

* Heterogeneous nuclear ribonucleoproteins, novel target antigens of autoantibodies in autoimmune disease?
Katrijn Op De Beéck (Leuven, Belgium)

* Occurrence of autoantibodies to calreticulin in oncological patients and patients from risk groups
Aneta Pekáriková (Prague, Czech Republic)

* Technical parameters of particle array development
Kai Großmann (Senftenberg, Germany)

* Performance evaluation of PR3-ANCA ELISAs
Matthew Hayman (Christchurch, New Zealand)

Discussion
FRIDAY
SEPTEMBER 04

08.30–10.00

METHODICAL ASPECTS AND DIAGNOSTIC STRATEGIES I
Co-Chairs: X. Bossuyt (Leuven, Belgium)
A. Kromminga (Hamburg, Germany)

08.30–09.00
Recommendations of the ACR committee on the standardization of autoantibody detection
Pier Luigi Meroni (Milan, Italy)

09.00–09.15
* Detection and differentiation of non-organ specific autoantibodies by a fully automated HEp-2 cell assay
Rico Hiemann (Dresden, Germany)

09.15–09.30
Contribution of immunofluorescence on formalin-fixed neutrophils in ANCA detection and differentiation
Elena Csernok (Lübeck, Germany)

09.30–09.45
Peptide resolved diagnostics in systemic autoimmune diseases: Potentials and pitfalls
Michael Mahler (Neuss, Germany)

09.45–10.00
Diagnosis of IgA-deficient coeliac disease by assay of IgG antibodies against deamidated gliadin (GAF3X)
Thomas Mothes (Leipzig, Germany)

10.00–10.30
COFFEE BREAK – POSTER AND EXHIBITION VIEWING

10.30–12.15

METHODICAL ASPECTS AND DIAGNOSTIC STRATEGIES II
Co-Chairs: Y. Shoenfeld (Tel-Hashomer, Israel)
P.L. Meroni (Milan, Italy)

10.30–11.00
Clinical performance characteristics of a laboratory test
Xavier Bossuyt (Leuwen, Belgium)
Stratification of autoantibody signatures in human sera by peptide epitope profiling

Hans-Jürgen Thiesen (Rostock, Germany)

ELISA using ectodomains of desmoglein 1 and 3 expressed in HEK293 for sensitive and specific detection of pemphigus autoantibodies

Wolfgang Schlumberger (Lübeck, Germany)

* Anti-Th/To antibodies in Italian scleroderma patients: Clinical and immunological correlations and comparison with patients with anti-centromere (ACA) antibodies

Angela Ceribelli (Brescia, Italy)

Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn’s disease

Dirk Roggenbuck (Dahlewitz, Germany)

ELISA for the detection of autoantibodies against DNA-bound lactoferrin in ulcerative colitis

Lars Komorowski (Lübeck, Germany)

EASI FORUM LUNCH MEETING

LUNCH BREAK – POSTER AND EXHIBITION VIEWING

Poster viewing

P27-P40  Connective tissue diseases and APS
FRIDAY
SEPTEMBER 04

13.30–14.30

BIOLOGY OF AUTOANTIGEN/AUTOANTIBODY SYSTEMS
Co-Chairs: M. Fritzler (Calgary, Canada)
            P. von Landenberg (Olten, Switzerland)

Inducible cytoplasmic ring/rod structures as targets of emerging human autoantibodies associated with viral infection and interferon therapy
Edward K.L. Chan (Gainesville, USA)

Clinical and Autoantibodies to DFS70/LEDGF: natural antibodies or sensors of cellular stress?
Carlos Casiano (Loma Linda, USA)

Circulating proteasomes and autoantibodies
Eugen Feist (Berlin, Germany)

14.30–15.45

BIOLOGICAL THERAPY OF AUTOIMMUNE DISEASES II
Co-Chairs: E. Feist (Berlin, Germany)
            W. van Venrooij (Nijmegen, The Netherlands)

Immune reactions induced by biologicals
Arno Kromminga (Hamburg, Germany)

* Measuring anti-adalimumab levels in the presence of adalimumab
Pauline van Schouwenburg (Amsterdam, The Netherlands)

Serological changes induced by B cell ablative therapy
Pierre Youinou (Brest, France)
DRESDEN PRICE ON THE STUDY OF AUTOANTIBODIES
Award Ceremony

COFFEE BREAK – POSTER AND EXHIBITION VIEWING

Poster viewing
P41-58 Organ specific autoimmune diseases

Departure to Weesenstein

Guided visit of the Castle of Weesenstein

Social Dinner
SATURDAY
SEPTEMBER 05
08.30–10.00

RHEUMATOID ARTHRITIS
Co-Chairs: E. Csernok (Lübeck, Germany)
F. Hiepe (Berlin, Germany)

08.30–09.00
Clinical relevance of rheumatoid arthritis associated autoantibodies
Günter Steiner (Vienna, Austria)

09.00–09.30
The rheumatic arthritis cycle
Walter J. van Venrooij (Nijmegen, The Netherlands)

09.30–09.45
* Novel autoantibody targets in early and seronegative rheumatoid arthritis
Klaartje Somers (Diepenbeek, Belgium)

09.45–10.00
Development of novel antibody markers for diagnostic protein biochips – The rheumatoid arthritis case study
Angelika Lueking (Dortmund, Germany)

10.00–10.30
COFFEE BREAK – POSTER AND EXHIBITION VIEWING

Poster viewing
P14-P18 Rheumatoid arthritis

10.30–12.00

AUTOIMMUNE NEUROLOGICAL DISEASES
Co-Chairs: K. Conrad (Dresden, Germany)
H.J. Willison (Glasgow, UK)

10.30–11.00
Peripheral neuropathies and antiglycolipid antibodies
Hugh J. Willison (Glasgow, UK)

11.00–11.30
Antiganglioside antibodies – A very heterogeneous family of biomarkers
René-Louis Humbel (Esch-sur-Alzette, Luxembourg)
Recombinant immunofluorescence assay for the detection of anti-glutamate receptor (type NMDA) antibodies in the differential diagnosis of autoimmune encephalopathies

*Klaus-Peter Wandinger (Lübeck, Germany)*

Antibodies against aquaporin-4 in neuromyelitis optica: cell-based assay vs. immunoprecipitation assay

*Dörte Hamann (Amsterdam, The Netherlands)*

* The lectures marked with asterisks are given by the candidates for the DRESDEN PRICE ON THE STUDY OF AUTOANTIBODIES.
POSTER EXHIBITION

Novel autoantibodies

**P1** Systematic development of novel antibody markers for diagnostic protein biochips – the prostate cancer case study
A. Kowald, G. Bartsch, H. Klocker, J. Beator, S. Müllner, A. Lueking (Düsseldorf, Germany)

**P2** Anti-p155/140 (anti-TIF1) autoantibodies in patients with cancer associated myositis detected in a single centre
J. Vencovský, H. Mann, I. Půtová, Z. Betteridge, H. Gunawardena, N. McHugh (Prague, Czech Republic)

**P3** The cell cycle protein Nop52 is a candidate target autoantigen
A. Swart, M. Mahler, M.J. Fritzler (Neuss, Germany)

**P4** Identification of inosine-1,2-monophosphate-dehydrogenase-2 as a novel autoantigen
M. Blüthner, H. Appelhans, I. Moosbrugger, C. Wiemann, D. Lenz, H.P. Seelig (Karlsruhe, Germany)

**P5** Heterogeneous nuclear ribonucleoproteins, novel target antigens of autoantibodies in autoimmune disease?

**P6** New autoantibodies in primary sclerosing cholangitis: reactivity with distinct immunodominant epitopes of sulfite oxidase
B. Preuß, C. Berg, F. Altenberend, M. Gregor, S. Stevanovic, R. Klein (Tübingen, Germany)

**P7** Sperm-associated antigen 16 isoform 2: A novel candidate autoantigen in multiple sclerosis
K. Somers, R. Hupperts, C. Zwanikken, P. Stinissen, V. Somers (Limburg, Belgium)
Methodical aspects

P8 Laboratory policies on the management of autoimmune diseases in a cohort of Italian laboratories
A. De Nicolo, M. Tampoia and Study investigators (Bari, Italy)

P9 ELISA using ectodomains of desmoglein 1 and 3 expressed in HEK293 for sensitive and specific detection of pemphigus autoantibodies

P10 Bioplex™2200 multiplex ANAscreen assay: a novel approach for the detection of antinuclear autoantibodies
S. Signorini, L. Lattuada, R. Colombo (Brescia, Italy)

P11 Comparison of light sources for measurement of single and multiplex bead assays

Therapy

P12 Corticosteroid-induced spinal epidural lipomatosis in the pediatric patients with chronic autoimmune disorders
J.C. Moeller, G. Hahn, F. Pessler (Dresden, Germany)

P13 Measuring anti-adalimumab levels in the presence of adalimumab
P. van Schouwenburg, G. Wolbink, L. Aarden, D. Wouters (Amsterdam, The Netherlands)
Rheumatoid arthritis

P14  Novel Autoantibody targets in early and seronegative rheumatoid Arthritis  
K. Somers, P. Geusens, M. Coenen, M. Blom, P. Stinissen,  
V. Somers (Limburg, Belgium)

P15  Development of novel antibody markers for diagnostic protein biochips – the rheumatoid arthritis case study  
A. Lueking, A. Kowald, M. Schneider, H.E. Meyer, J. Beator,  
S. Müllner (Düsseldorf, Germany)

P16  Autoantibody production in early undifferentiated arthritis  
O. Abade, I. Abreu, F. Pimentel, M. Parente, J. Vaz Patto, R.  
Figueiredo, D. Ligeiro, C. Miguel, A. Teixeira, H. Trindade  
(Lisboa, Portugal)

P17  Diagnostic sensitivity and specificity for rheumatoid arthritis by the bio-rad kallestad ANTI-CCP II assay  
Kumfert, T. Prestigiacomo (Hercules, USA)

P18  Comparison of the research-based anti-Sa with the EUROIMMUN commercial anti-Sa ELISA to monitor rheumatoid arthritis activity  
M. Lora, J. Rotman, H.A. Ménard, D. Kast, C. Daehnrich, W.  
Stoecker, W. Schlumberger (Lübeck, Germany)

Vasculitides/ANCA

P19  Gender differences in oxidative stress and apoptosis of vascular cells induced by autoantibodies specific to RLIP76  
T. Colasanti, P. Margutti, P. Matarrese, F. Delunardo, B. Ascione,  
D. Vacirca, W. Malorni, E. Ortona (Rome, Italy)
P20  Clinical relevance of ANCA in routine care  
Y. Ben Haj Hmida, D. Bouzid, S. Boukthir, M. Ben Ayed, H. Masmoudi (Sfax, Tunisia)

P21  ANCA or other neutrophil specific antibodies (NSA)  
L. Cebecauer, V. Král, J. Lupač, I. Lochman (Pieštany, Slovak Republic)

P22  Autoimmunity in patients with anti-neutrophil cytoplasmic antibodies: retrospective analysis of an Italian cohort of ANCA positive patients  
C. Defendenti, M. Francesca Spina, M. Longo, S. Bollani, A. Cereda, S. Saibeni, A. Reina, G. Guercilena, S. Bruno, M. Saudelli, F. Atzeni, P. Sarzi-Puttini (Milan, Italy)

P23  A novel immunofluorescence assay for the differentiation of pANCA and ANA  
I. Knüttner, T. Büttner, J. Scholka, D. Roggenbuck, U. Anderer (Dahlewitz, Germany)

P24  Performance evaluation of PR3-ANCA ELISAs  

P25  A novel PR3-ANCA ELISA with a mixture of human purified and recombinant PR3 as solid-phase antigen  
A. Radice, L. Bianchi, A. Palumbo, R.A. Sinico (Milan, Italy)

P26  High sensitive detection of autoantibodies to proteinase 3 (PR3) – a novel third generation capture ELISA  
D. Roggenbuck, T. Büttner, L. Hoffmann, H. Schmechta, D. Reinhold, K. Conrad (Dahlewitz, Germany)

Connective tissue diseases and APS

P27  VEGF gene polymorphisms in patients with systemic Lupus erythematosus  
L. Ostanek, D. Bobrowska-Snarska, M. Ostanek, A. Bińczak-Kuleta, A. Ciechanowicz, M. Brzosko (Szczecin, Poland)
Wednesday, September 02 (16.00 p.m.)
Until Saturday, September 05 (10.30 a.m.)

P28 Anti-IFI16 autoantibodies: A new marker in autoimmunity
S. Costa, M. Mondini, V. Caneparo, Italian FIRMA Group, S. Landolfo, M. Gariglio (Turin, Italy)

P29 Evaluation of a novel dsDNA ELISA for SLE disease activity measurement
M. Mahler, M. van Liempt, J. Schulte-Pelkum, S. Schneider, T. Alexander, A. Kromminga, M. Fooke, F. Hiepe (Neuss, Germany)

P30 Effect of antigen affinity and isotype specificity on the diagnostic efficiency of anti-dsDNA autoantibody tests in systemic Lupus erythematosus patients
B. Schlüter, G. Bonsmann, M. Gaubitz, P. Willeke (Münster, Germany)

P31 Current status of anti-dsDNA antibody diagnostics in the hospital Laborverbund
R. Tripmacher, C. Kuznia, D. Roggenbuck, T. Büttner, B. Radau, K. Conrad, V. Jansen (Bernau, Germany)

P32 Anti-actinin antibodies in systemic lupus erythematosus
Y. Thabet, A. Achour, A. Mankai, W. Sakly, Y. Renaudineau, P. Youinou, I. Ghedira (Monastir, Tunisia)

P33 Decreased nucleosome releasing factor activity in patients with systemic lupus erythematosus
F. Stephan, R. Manoe, B. Zwart, I. Bulder, L. Aarden, S. Zeeleneder (Amsterdam, The Netherlands)

P34 Anti-Th/To antibodies in Italian scleroderma patients: Clinical and immunological correlations and comparison with patients with anti-centromere (ACA) antibodies
**P35**  Anti-CENP-A and anti-CENP-B antibodies show high concordance and similar clinical associations in patients with systemic sclerosis despite completely different underlying protein sequences

K. Hanke, C.S. Brueckner, M. Becker, W. Meyer, W. Schlumberger, G. Riemekasten (Berlin, Germany)

**P36**  Evaluation of the in-house developed dot-blot and ELISA for the detection of anti-PM/scl100 autoantibodies in systemic autoimmune diseases

L. Maes, K. Op De Beéck, K. Van Den Bergh, P. Verschueren, R. Westhovens, B. Blockmans, M. Mahler, X. Bossuyt (Leuven, Belgium)

**P37**  Anti-PM/Scl-antibodies in systemic sclerosis: Comparison between PM1-Alpha ELISA and a line assay with recombinant PM/Scl-75c and PM/Scl-100

M. Mahler, M. Siegemund, W. Meyer, M. Petschinka, M. J. Fritzler (Neuss, Germany)

**P38**  Anti-argonaute2 (Ago2/Su) and -Ro antibodies are the common autoantibody specificities in primary anti-phospholipid syndrome (PAPS)


**P39**  The antiphospholipid syndrome in acute ischemic stroke patients with insulinresistance

O. Virstyuk, R.D. Gerasymchuk, N. Virstyuk, R. Portyuk (Ivano-Frankivsk, Ukraine)

**P40**  The antiphospholipid antibodies in patients with chronic heart failure

N. Virstyuk, V. Neyko, E. Cherkachuna, O. Virstyuk (Ivano-Frankivsk, Ukraine)
Organ specific autoimmune diseases

P41 Immortalized B cell lines from multiple sclerosis patients produce antibodies that bind an oligodendrocyte precursor cell line

P42 Analysis of autoantibody profiles in cerebrospinal fluid and serum of a relapsing-remitting MS patient with active disease using serological antigen selection
C. Govarts, K. Somers, R. Hupperts, P. Jongen, P. Stinissen, V. Somers (Limburg, Belgium)

P43 Anti-tau antibodies in patients with multiple sclerosis
J. Švarcová, L. Fialová, A. Bartos, L. Cechova, D. Dolezil, I.M. Malbohan (Prague, Czech Republic)

P44 Avidity of antibodies against tau protein in patients with multiple sclerosis
L. Fialová, J. Švarcová, A. Bartos, I.M. Malbohan (Prague, Czech Republic)

P45 Detection of antibodies to aquaporin-4 by indirect immunofluorescence employing a standardized recombinant target antigen
S. Jarius, C. Probst, K. Borowski, D. Franciotta, B. Woldemann, W. Stöcker, K.P. Wandinger (Lübeck, Germany)

P46 Recombinant immunofluorescence assay for the detection of anti-glutamate receptor (type NMDA) antibodies in the differential diagnosis of autoimmune encephalopathies
K.P. Wandinger, J. Dalmau, K. Borowski, C. Probst, K. Fechner, W. Stöcker (Lübeck, Germany)
P47 Co-incidence of serum anti-ganglioside antibodies and microbial infection in patients with inflammatory peripheral neuropathy
I. Janatkova, K. Malickova, A. Potmesilova, B. Potuznikova, T. Fucikova (Prague, Czech Republic)

P48 Ganglioside antibodies in amyotrophic lateral sclerosis
U. Wurster, K. Kollewe, B. Mohammadi, T. Sinzenich, S. Petri (Hannover, Germany)

P49 TSH receptor antibody (TRAb) assays using human monoclonal autoantibody M22 are more sensitive than bovine TSH based assays
K. Zöphel, P. von Landenberg, D. Roggenbuck, G. Wunderlich, T. Grüning, J. Kotzerke, K.J. Lackner, B. Rees Smith (Dresden, Germany)

P50 Prevalence of ovarian antibodies in women with unexplained recurrent pregnancy loss
M. Cojocaru, I.M. Cojocaru, I. Silosi, S. Rogoz (Bucharest, Romania)

P51 Validation of Bio-Rad gastrointestinal assays for use on the EVOLISTM and EVOLISTM Twin Plus systems
X. Guo, R. Lerner, L. Sana, W. Kumfert, T. Prestigiacomo (Hercules, USA)

P52 Antibodies against deamidated gliadin as a novel serologic marker for celiac disease
M. Miler, A. Tesija Kuna, O. Zaja Franulovic, N. Vrkić (Zagreb, Croatia)

P53 Deamidated gliadin antibodies facilitate diagnosis in celiac disease
T. Krieger, F. Haag (Hamburg, Germany)
**P54** Diagnosis of IgA-deficient coeliac disease by assay of IgG antibodies against deamidated gliadin (GAF3X)

**P55** Use of recombinant autoantigens in profiling of PBC associated antibodies
A. Neininger, J. Kaiser, J. Weyand, C. Berg, S. Buck, R. Klein, H. Haubruck, B. Liedvogel (Freiburg, Germany)

**P56** Autoantibodies to asialoglycoprotein receptor (ASGPR) measured by a novel ELISA - revival of a disease-activity marker in autoimmune hepatitis (AIH)
G. Hausdorf, E. Feist, K. Conrad, D. Roggenbuck, T. Büttner, C. Berg, R. Klein (Berlin, Germany)

**P57** Antineutrophil cytoplasmic antibodies and HLA II in Ulcerative Colitis Tunisian patients
D. Bouzid, Y. Ben Haj Hmida, A. Amouri, N. Mahfouth, A. Kammoun, M. Ben Ayed, H. Makni, N. Tahri, H. Masmoudi (Sfax, Tunisia)

**P58** Fine specificity of serum IgA and IgG autoantibodies against calreticulin in oncological patients
D. Sánchez, A. Pekárková, L. Palová-Jelínková, T. Mothes, H. Tlaskalová-Hogenová, L. Tučková (Prague, Czech Republic)
The modern Lecture Hall Centre of the Technical University of Dresden is located on the University Campus in the South of the city, about 15 minutes walk away from the Central Railway Station.

Address of the congress venue:
Hörsaalzentrum der Technischen Universität Dresden
Bergstrasse 64, 01069 Dresden

September 02: 12.00 - 21.30
September 03: 08.00 - 19.00
September 04: 08.00 - 16.30
September 05: 08.00 - 12.30

Phone +49 351 463 48812 and +49-160 98 35 87 47
Fax +49 351 463 48814

Karsten Conrad, Germany
Edward K.L. Chan, USA
Marvin Fritzler, Canada
René-Louis Humbel, Luxembourg
Yehuda Shoenfeld, Israel
Philipp von Landenberg, Switzerland

Carlo Chizzolini, Switzerland
Elena Csernok, Germany
Falk Hiepe, Germany
Arno Kromminga, Germany
Pier Luigi Meroni, Italy
Günter Steiner, Austria
Walter J. van Venrooij, The Netherlands
Hugh J. Willison, UK
Pierre Youinou, France

English, no simultaneous translation
Informations

Organization
(Registration, Reservation, Exhibition)

Silke Zwjatkow
GFID e.V.
Veilchenweg 28
D-01326 Dresden
Phone +49 351 26 32 279
Fax +49 351 26 32 280
e-mail: kontakt@gfid-ev.de

Registration fee
(on site)

Participants EUR 420
GFID members EUR 350
Students/Residents EUR 220
One day tickets EUR 140

(includes unlimited access to all scientific sessions, welcome reception, industrial exhibition, conference book = 6th volume of the book series "Autoantigens, Autoantibodies, Autoimmunity", coffee and lunch breaks)

Members of the Dresden University are free of charge.
Welcome reception in the Lecture Hall Center of the Technical University of Dresden

Guided visit and Social Dinner in the Castle of Weesenstein (90 €)
Weesenstein Castle in the Müglitztal valley is one of the most beautiful tourist destinations before the gates of Dresden. The 700-year-old castle on a rock above the village presents its visitors Saxon history from the Middle Ages through to the 19th century. Especially delightful is a walk in the castle gardens. For more information, please see www.schloss-weesenstein.de.

16.30: Departure by bus starting from the congress venue
17.30: Guided visit of the Castle of Weesenstein
18.30: Social Dinner

We hope to welcome you again at our 10th Dresden Symposium on Autoantibodies, September 22–25, 2011.
The following companies participate in the industrial exhibition and/or have made a generous sponsoring (in alphabetical order):

**A. MENARINI DIAGNOSTICS DEUTSCHLAND.**
Division der BERLIN-CHEMIE AG (Berlin, Germany)
www.menarini.com

Abbott GmbH & Co KG (Wiesbaden, Germany)
www.abbottdiagnostics.de

Aesku.Diagnostics e.K. (Wendelsheim, Germany)
www.aeskulab.com

Beckman Coulter GmbH (Krefeld, Germany)
www.beckmancoulter.com

Bio-Rad Laboratories, Inc. (Hercules, USA)
www.bio-rad.com

BioSystems S.A. (Barcelona, Spain)
www.biosystems.com

Bühlmann Laboratories (Schönenbuch, Switzerland)
www.buhllmannlabs.ch

Diarect AG (Freiburg, Germany)
www.diarect.com

DLD Diagnostika GmbH (Hamburg, Germany)
www.dld-diagnostika.de

Dr. Fooke Laboratorien GmbH (Neuss, Germany)
www.fooke-labs.de

EUROIMMUN Medizinische Labordiagnostika AG
(Lübeck, Germany)
www.euroimmun.de
GA Generic Assays GmbH (Dahlewitz, Germany)
www.genericassays.com

hospital Laborverbund Brandenburg Berlin GmbH (Bernau, Germany)
www.labor-bernau.de

HUMAN GmbH (Wiesbaden, Germany)
www.human.de

Instrumentation Laboratory GmbH (Kirchheim, Germany)
www.il-ger.de

Medical and Biological Laboratories Co., Ltd. (Nagoya, Japan)
www.mbl.co.jp

Medipan GmbH (Dahlewitz, Germany)
www.medipan.de

Mikrogen GmbH (Neuried, Germany)
www.mikrogen.de

ORGENTEC Diagnostika GmbH (Mainz, Germany)
www.orgentec.com

Phadia GmbH (Freiburg, Germany)
www.phadia.com

Roche Pharma AG (Grenzach-Wyhlen, Germany)
www.roche.com

The Binding Site GmbH (Schwetzingen, Germany)
www.bindingsite.com

We thank these companies for helping to make this symposium successful.
Three Technologies, One Solution

IFA, EIA, Multiplex

From the reknown Kallestad IFA products to the revolutionary BioPlex 2200, Bio-Rad provides laboratories and clinicians with innovative solutions.